#heart-failure

All articles tagged with "heart-failure"

Health

Semaglutide improved heart measures in HFpEF substudy

Key Takeaways

The randomized imaging substudy included 49 people with obesity-related HFpEF.
Semaglutide improved left-atrial reservoir strain and indexed early ventricular filling versus placebo.
Imaging improvements were associated with lower exercise pulmonary artery wedge pressure.

DT Editorial Team·Nov 11, 2026·via nature.com

More in Health→

Experimental mRNA therapy promotes repair after heart attack damage

Health

mRNA Therapy Shows Heart Repair Potential After Heart Attack

Key Takeaways

Researchers used mRNA to temporarily activate Myc and Cyclin T1 in mouse heart cells.
Treated mice pumped roughly 10% more blood per heartbeat than mock-treated mice after heart attack damage.
The work is preclinical and requires larger-animal and human studies.

DT Editorial Team·Nov 9, 2026·via medicalxpress.com

More in Health→

Single iron infusion improved exercise capacity in people with the most common form of heart failure

Health

Iron Infusion Boosts Exercise Capacity in HFpEF Trial

Key Takeaways

IRON-MET HFpEF randomized 65 people with symptomatic HFpEF and iron deficiency.
Peak VO₂ improved by about 10% after one ferric derisomaltose infusion and was unchanged with placebo.
Larger studies are needed to confirm longer-term clinical benefit.

DT Editorial Team·Nov 8, 2026·via medicalxpress.com

More in Health→

Disability burden linked to alcohol-related cirrhosis and heart failure projected to rise sharply by 2050

Health

Alcohol-Related Cirrhosis and Heart Failure Burden May Rise by 2050

Key Takeaways

The analysis examined disability trends from 1990 to 2023 and modeled outcomes through 2050.
The United States, Central Europe and Eastern Europe are projected to see increases of about 50% to 67%.
Adults aged 70 and older had YLD rates 10 to 16 times those of people aged 15 to 49.

DT Editorial Team·Oct 17, 2026·via medicalxpress.com

More in Health→

How heart failure reshapes bone marrow to create inflammation-related immune memory

Health

Heart Failure May Reprogram Bone Marrow Immunity

Key Takeaways

Researchers studied how heart failure changes interactions between bone-marrow support cells and blood-forming stem cells.
Heart failure reduced an HBEGF-producing Lepr-positive stromal-cell population in mouse models.
The findings identify a possible mechanism for persistent inflammation-related immune memory in heart failure.

DT Editorial Team·Oct 16, 2026·via medicalxpress.com

More in Health→

Spinach nanoparticles help failing rat hearts via 'borrowed photosynthesis'

Science

Spinach Nanoparticles Use Light to Aid Failing Rat Hearts

Key Takeaways

Researchers extracted thylakoid membranes from spinach and formed nanoscale particles.
Heart-cell membrane coatings improved uptake in cultured rat cardiac cells.
Red-light activation increased ATP in treated cells and was associated with improved measures in rats with induced heart failure.
The research is preclinical and does not demonstrate a human treatment.

DT Editorial Team·Oct 11, 2026·via phys.org

Nearly 1 in 3 Type 2 Diabetes Patients Develop Cardiorenal Disease or Die Within 5 Years

Key Takeaways

A study of nearly 1.62 million adults with newly diagnosed type 2 diabetes was presented at the European Association for the Study of Diabetes annual meeting in Milan.
Within five years of diagnosis, 19.0% of patients developed chronic kidney disease first versus 8.3% who developed heart failure first.
After chronic kidney disease, the five-year risk of heart failure was 22.7%; after heart failure, the five-year risk of chronic kidney disease was 42.0%.
The composite risk of chronic kidney disease, heart failure or death was 32.9% at five years and 55.1% at 10 years.

DT Editorial Team·Oct 2, 2026·via medicalxpress.com

More in Health→

Targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy | Joseph C. Wu (via www.linkedin.com)

Science

Atypical GPCR Signaling Tapped as a Target for Cardiac Fibrosis Therapy

Key Takeaways

Science lists a report on targeting an atypical G protein–coupled receptor signaling pathway for cardiac fibrosis therapy in Volume 393, Issue 6818 (September 2026).
Cardiac fibrosis replaces working muscle with stiff connective tissue, contributing to heart failure and arrhythmia, and current drugs treat upstream causes rather than the scar itself.
Atypical, non-canonical GPCR signaling branches can be engaged selectively, which could allow fibrosis-linked pathways to be interrupted without shutting down normal cardiac physiology.
Key hurdles include fibroblast selectivity, timing of intervention, sustained cardiac delivery, and clinical endpoints that measure fibrosis and function.

DT Editorial Team·Sep 27, 2026·via science.org

Approved Cancer Drug SAHA May Shield the Heart During Doxorubicin Chemotherapy

Key Takeaways

Heidelberg researchers identified the molecular signaling pathway through which doxorubicin damages heart muscle, centered on topoisomerase IIβ and MEF2.
SAHA, a drug already approved for certain cancers, attenuated harmful mechanisms in heart muscle cells in cell-based and animal studies.
SAHA protected against chronic doxorubicin-induced cardiac dysfunction, fibrosis and transcriptional remodeling in vivo.
Measurable changes in cardiac function appear in roughly one-quarter of doxorubicin-treated patients, raising long-term heart failure risk.

DT Editorial Team·Sep 21, 2026·via medicalxpress.com

More in Health→

$Myeloperoxidase inhibition with mitiperstat in heart failure with preserved or mildly reduced ejection fraction: a randomized phase 2b trial | Nature Medicine (via www.nature.com)$

Health

Mitiperstat Misses Symptom and Exercise Endpoints in HFpEF Trial

Key Takeaways

Phase 2b, multicenter, randomized, double-blind, placebo-controlled, three-arm trial of the MPO inhibitor mitiperstat in heart failure with ejection fraction above 40%.
711 patients (45% women) were randomized 1:1:1 to mitiperstat 2.5 mg, mitiperstat 5 mg or placebo, with 48 weeks of treatment.
Co-primary endpoints at 16 weeks — KCCQ-TSS and 6-minute walk distance — both missed: placebo-corrected differences of –1.4 points (P = 0.29) and 3.8 m (P = 0.28).
No secondary endpoint improved, including natriuretic peptides and inflammatory markers up to 48 weeks and echocardiographic parameters up to 24 weeks.

DT Editorial Team·Sep 10, 2026·via nature.com

More in Health→

Frontiers | Stem cell therapy for heart failure in the clinics: new perspectives in the era of precision medicine and artificial intelligence (via www.frontiersin.org)

Health

Stem Cell Heart Failure Trial Shows Gains and Risks

Key Takeaways

A 20-patient randomized trial paired bypass surgery with or without hiPSC-derived cardiomyocyte injections.
No sustained ventricular tachycardia or tumorigenicity was observed over the primary safety follow-up.
All treated patients developed early accelerated idioventricular rhythm, and two had significant ventricular tachycardia.
Secondary analyses showed stronger gains in walk distance, myocardial perfusion, and wall thickening than surgery alone.

DT Editorial Team·Aug 20, 2026·via nature.com

More in Health→

Health

Polypill Strategy Boosts Heart Function in Underserved HF Patients: POLY-HF Trial

Key Takeaways

POLY-HF randomized 212 adults with HFrEF to a polypill or enhanced usual care.
Polypill improved LVEF by 3.3 percentage points more than usual care at 6 months.
Heart failure hospitalizations/ED visits were 60% lower with polypill.
Adherence was higher with polypill (79% vs 54%) by blood drug levels.

DT Editorial Team·Jul 3, 2026·via nature.com

More in Health→

Enlisting pharmacists and nurse practitioners in medication management can fill critical gaps

Health

Study Backs Bigger Role for Pharmacists in Heart Failure Care

Key Takeaways

A peer-reviewed economic model found expanded pharmacist- and nurse practitioner-led medication management for heart failure could be cost-effective.
The study projects that patients would live longer and spend less time in the hospital under the enhanced-care scenario.
Researchers frame the approach as a roadmap for improving uptake of proven therapies where specialist access is limited.

DT Editorial Team·Jun 29, 2026·via medicalxpress.com

More in Health→

Health

Engineered heart muscle reaches an early clinical milestone in heart failure

Key Takeaways

A Nature Medicine highlight says engineered heart muscle showed promising early outcomes in advanced heart failure.
The therapy uses allografts derived from induced pluripotent stem cells.
The report supports further clinical investigation rather than broad clinical use.

DT Editorial Team·Jun 17, 2026·via nature.com

More in Health→

RNA therapy for genetic heart failure moves closer to patients after lab gains

Health

RNA therapy shows early promise against inherited heart failure

Key Takeaways

The study targeted the PLN R14del variant linked to inherited cardiomyopathy.
RNA treatment reduced mutant protein aggregation in heart-cell models.
Researchers used patient-derived tissue and stem-cell-based models.

DT Editorial Team·May 29, 2026·via medicalxpress.com

More in Health→

Heart patch engineered from stem cells revved up weakened hearts

Health

Stem-cell heart patch shows early promise in advanced heart failure trial

Key Takeaways

A stem cell-based muscle patch improved heart pumping in a small trial.
The study involved patients with advanced heart failure.
Researchers described the result as a promising first clinical step.

DT Editorial Team·May 28, 2026·via statnews.com

More in Health→

Health

Low-Dose Digoxin Misses Primary Goal but Hints at Fewer Heart Failure Events

Key Takeaways

The DECISION trial randomized 1,001 heart failure patients to low-dose digoxin or placebo.
The primary composite outcome was not significantly reduced in the digoxin group.
Worsening heart failure events were numerically lower with digoxin, suggesting a possible signal short of statistical significance.

DT Editorial Team·May 12, 2026·via nature.com

More in Health→

Health

Why Researchers Are Taking Heart Tissue Into Space

Key Takeaways

Researchers are using microgravity to study heart failure mechanisms faster than on Earth.
Space conditions may also improve the structure of engineered heart tissues and organoids.
The work could inform drug discovery, pre-transplant care, and future cardiac repair strategies.

DT Editorial Team·Apr 25, 2026·via medicalxpress.com

More in Health→

Health

New Pacing Approach for Heart Failure Patients May Cut Repeat Procedures

Key Takeaways

EHRA 2026 featured late-breaking research on left bundle branch area pacing for cardiac resynchronization.
The presentation described the method as effective and practical.
Researchers said the approach may reduce repeat surgeries and shorten implant procedures.

DT Editorial Team·Apr 14, 2026·via medicalxpress.com

More in Health→

Health

Screening-Detected Atrial Fibrillation Is Often Accompanied by Heart Failure, Conference Report Says

Key Takeaways

A presentation at EHRA 2026 reported that heart failure is common in people with screening-detected atrial fibrillation.
The finding suggests newly identified atrial fibrillation may coincide with broader cardiovascular disease.
The supplied source material does not include detailed methods or prevalence figures.
The report underscores the importance of follow-up assessment after a positive screening result.

DT Editorial Team·Apr 13, 2026·via medicalxpress.com

More in Health→